

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 25 MAY 2023

At the annual general meeting (the “AGM”) of Genscript Biotech Corporation (the “Company”) held on 25 May 2023, all the proposed resolutions put to the vote have been taken by way of poll, as set out in the notice of AGM dated 3 May 2023.

As at the date of the AGM, the total number of issued shares of the Company was 2,118,058,529 shares of US\$0.001 each, which was the total number of shares entitling the holder to attend and vote on the resolutions at the AGM. Computershare Hong Kong Trustees Limited, the trustee of the restricted share award schemes adopted by the Company on 22 March 2019 and 23 August 2021, who is currently holding 10,212,126 unvested shares with voting rights attached (representing approximately 0.48% of the number of the issued shares of the Company) has abstained from voting on any of the resolutions at the AGM. Save as disclosed above, there were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) nor any shares of holders required under the Listing Rules to abstain from voting at the AGM.

All the directors of the Company were present at the meeting either in person or by means of telecommunication

The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the “Directors”) and auditors of the Company for the year ended 31 December 2022.	1,201,181,663 (99.960388%)	476,000 (0.039612%)
2.	(A) (i) To re-elect Ms. Wang Jiafen as non-executive Director.	1,109,171,299 (92.303435%)	92,486,362 (7.696565%)
	(ii) To re-elect Mr. Dai Zumian as independent non-executive Director.	1,161,626,942 (96.668708%)	40,030,721 (3.331292%)

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
	(iii) To re-elect Mr. Pan Jiuan as independent non-executive Director.	1,194,508,583 (99.405065%)	7,149,080 (0.594935%)
	(iv) To re-elect Dr. Wang Xuehai as independent non-executive Director.	1,199,870,969 (99.851314%)	1,786,694 (0.148686%)
	(B) To authorize the board of Directors (the “ Board ”) to fix remuneration of the Directors.	1,201,594,884 (99.994776%)	62,779 (0.005224%)
3.	To re-appoint Ernst & Young, Certified Public Accountants, as the auditor of the Company and authorize the Board to fix remuneration of auditor.	1,199,416,314 (99.813479%)	2,241,349 (0.186521%)
4.	(A) To give a general and unconditional mandate to the Directors to allot, issue and deal with additional shares not exceeding 20% of the number of issued shares of the Company.	1,073,096,572 (89.301355%)	128,561,091 (10.698645%)
	(B) To give a general and unconditional mandate to the Directors to repurchase shares not exceeding 10% of the number of issued shares of the Company.	1,199,277,208 (99.801902%)	2,380,455 (0.198098%)
	(C) To extend the authority given to the Directors pursuant to the ordinary resolution No. 4(A) to issue shares by adding the number of shares repurchased under the ordinary resolution No. 4(B).	1,074,953,086 (89.455851%)	126,704,577 (10.544149%)
SPECIAL RESOLUTION		No. of Votes (%)	
		For	Against
5.	To approve the proposed amendments to the existing memorandum of association and articles of association of the Company and to adopt the third amended and restated memorandum and articles of association of the Company as the new memorandum and articles of association of the Company.	1,197,379,663 (99.643992%)	4,278,000 (0.356008%)

As more than 50% of votes were casted in favour of each of the above ordinary resolutions numbered 1 to 4, and 75% or above of votes were casted in favour of the above special resolution numbered 5, all of the above resolutions were approved by the shareholders of the Company.

By order of the Board
Genscript Biotech Corporation
Meng Jiange
Chairman and Executive Director

Hong Kong, 25 May 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

**For identification purposes only*